Table 6. Relative Efficacy of... | American Society of Hematology

Table 6.

Relative Efficacy of Thioguanine and Etoposide in Different Morphologic Subclasses of AML

Endpoint	Allocated Treatment	FAB Type
		M0	M1	M2	M3	M4	M5	M6	M7	Other/Unknown

CR rate (%)	TG	63	76	85	85	79	84	89	70	69
	VP	50	80	89	80	84	88	84	67	75
5-yr DFS	TG	27	38	40	52	47	40	34	16	27
(from CR)	VP	53	31	45	63	40	46	31	52	35
5-yr survival	TG	16	34	41	59	39	33	44	23	27
(all patients)	VP	24	33	44	58	37	43	23	32	28

Endpoint	Allocated Treatment	FAB Type
		M0	M1	M2	M3	M4	M5	M6	M7	Other/Unknown

CR rate (%)	TG	63	76	85	85	79	84	89	70	69
	VP	50	80	89	80	84	88	84	67	75
5-yr DFS	TG	27	38	40	52	47	40	34	16	27
(from CR)	VP	53	31	45	63	40	46	31	52	35
5-yr survival	TG	16	34	41	59	39	33	44	23	27
(all patients)	VP	24	33	44	58	37	43	23	32	28

Tests for heterogeneity: CR rate: χ²₈ = 4.8, P = .8; DFS: χ²₈ = 7.5, P = .5; Survival: χ²₈ = 3.9, P = .9. Tests for interactions M4/M5 v M0/M1/M2/M3/M6/M7: CR rate: χ²₁ = 0.7, P = .4; DFS: χ²₁ = 0.3, P = .6; Survival: χ²₁ = 0.1, P = .7.

View Large

This Feature Is Available To Subscribers Only